Management policies for patients with germ-cell tumours have been changing rapidly over the past few years. The dramatic improvement in prognosis for nonseminomatous germ-cell tumours has overshadowed the more subtle developments in the management of seminomas. The traditional approach to the treatment of seminomas has been heavily based on radiotherapy, even for advanced disease. Prophylactic radiotherapy, for example to the mediastinum and supraclavicular fossa in patients with nodal disease below the diaphragm, has been widely used. It is now apparent that seminomas are as sensitive to cytotoxic chemotherapy as are the nonseminomatous tumours (Einhorn & Williams, 1980; Ball et al., 1982; Schuette et al., 1985) . This, together with improvements in diagnostic imaging, and a desire to minimize the morbidity of therapy has prompted re-evaluation of treatment policies for seminoma of the testis (Oliver et al., 1984) .
In order to evaluate any new treatment policy it is important to have adequate data on the results achieved by the traditional policy. This applies not just to survival and relapse-free survival but also to the identification of factors which might affect prognosis. This review attempts to provide such data.
Patients and methods

Patients
All patients referred to the Department of Clinical Oncology, Western General Hospital, Edinburgh, with a diagnosis of germ-cell tumour during the period 1970 to 1981 inclusive have been reviewed. The department of Clinical Oncology is a regional centre serving a defined population and the observed number of referrals corresponds closely to the known incidence in the population served by the department.
A total of 336 patients were referred. All tumours were classified using the TTP classification (Thackray & Crane, 1976 (UICC, 1978) and the Royal Marsden Hospital staging system (Peckham et al., 1981) Using this technique the dose to the remaining testis is within the range 75-150cGy. If scrotal orchiectomy or transscrotal biopsy had been performed then the whole scrotum was included within the field.
All patients with Stage II disease received subdiaphragmatic irradiation using the fields described. In some patients the involved nodes were treated with additional radiotherapy using localized fields. Some patients received prophylactic supradiaphragmatic radiotherapy. A central dose of 3000 cGy in 20 daily fractions was given using parallel opposed fields to a volume encompassing the mediastinum and left supraclavicular fossa. Supradiaphragmatic radiotherapy was not usually started until at least three weeks after the completion of radiotherapy to the para-aortic nodes.
Patients with Stage III or IV disease received individualized therapy. Only three patients were treated with cisplatinum since most of the patients were treated before this drug was available.
Methods
The date of diagnosis has been defined as the date of the surgical procedure which yielded the tissue from which the diagnosis of seminoma was made: usually this was the date of orchiectomy. Only one patient has been lost to follow up within two years of treatment: he is assumed to have died from disease. Figure 1 . Figure 2 shows the survival curve for the 60 patients with TI primary tumours compared with the curve for the 50 patients whose primary tumours were T2, T3 or T4. The survival with a TI primary was 92% at 5 and 10 years. The survival for patients with primary tumours T> 1 was 79% at 5 years and 75% at 10 years. This difference is statistically significant (P <0.02). Lymphography was performed in 78 patients who were shown to have Stage I disease, their 5 and 10 year survival rates were 96.11%. There were 38 patients with Ti primary tumours and Stage I disease who had lymphography as part of their initial staging. The 5 and 10 year actuarial survival rate in this group is 100%. Only two of these patients relapsed, secondary therapy was successful and they survive disease-free. There were 24 patients with clinical stage I disease who did not have lymphography. Their actuarial survival at 5 and 10 years was 79.2%.
Seven patients with Stage I seminoma died; two relapsed initially in lung and supra-diaphragmatic nodes; five relapsed initially in mediastinal or supraclavicular nodes. A further five patients with Stage I seminoma were successfuly treated for relapse. One patient relapsed in the prostate; two relapsed in lung; one relapsed in nodes above the diaphragm. Ten patients with Stage II disease died from seminoma: four with Stage IIA, and six with Stage IIB or IIC. Of the patients in Stage IIA one had had prophylactic radiotherapy above the diaphragm and three had not. The patient who had been irradiated prophylactically relapsed in mediastinal nodes. The sites of relapse in the three other patients were brain, bone, and supraclavicular nodes. Of the patients with Stage IIB or IIC disease two had prophylactic irradiation above the diaphragm. Both patients initially relapsed in the region that had been treated prophylactically. Of the four patients who were treated by radiotherapy only to the nodes below the diaphragm one died from uncontrolled intraabdominal disease, two died from liver metastases and one died from uncontrolled disease above the diaphragm. One patient who presented with Stage II seminoma relapsed in lung and was successfully treated with thoracic irradiation.
There has been a definite improvement in the overall prognosis for all treated patients during the study period. The 5 year survival rate for patients treated before 1973 is 64.8%. The 5 year survival rate for patients treated after 1979 is 96.6% (P<0.01). The actuarial survival curves for these two groups are shown in Figure 3 .
Three patients have died from causes other than seminoma. One patient died from unexplained encephalopathy with no evidence of tumour. One patient was treated for seminoma in 1974, in 1977 he developed Hodgkin's disease and was treated with MOPP (mustine, vincristine, procarbazine, prednisolone There are few data on tumour marker levels at the time of relapse. None of the four patients who had AFP measured had elevated levels; similarly none of the three patients who had BHCG measured had elevated levels. Six patients had serum LDH measured at relapse: in three the levels were elevated, in three they were normal.
The major morbidity from treatment is summarised in Table III . In addition to the data summarised in Table III the following late complications have been observed. Individual patients treated with abdominal irradiation suffered from: lower limb ischaemia; myocardial infarction; large bowel stricture (post-radiation fibrosis); diverticular disease; gluten sensitive enteropathy; depression/alcohol abuse. Individual patients treated with radiotherapy above and below the diaphragm developed: pulmonary fibrosis; acute cholecystitis; large bowel fibrosis/stricture. As with any analysis of possible complications of treatment it is difficult to be certain which of these various problems can be directly attributed to the radiotherapy. (Calman et al., 1979; Schultz et al., 1984; Thomas et al., 1982) .
A striking, and gratifying, improvement in prognosis occurred between the earlier and latter years of the study period. The overall actuarial 5-year survival increased from 64.8% to 96.6%. There. was no obvious explanation for this change. (Oliver et al., 1984 The availability of effective therapy for metastatic disease has transformed the overall prognosis for patients with nonseminomatous germ-cell tumours (NSGCT) (Einhorn & Williams, 1980; Newlands et al., 1983 ). This factor is of less importance for seminomas. Very few patients present with, or develop, haematogenous metastases. Certainly the improved prognosis in Edinburgh cannot be explained by improvements in therapy for disseminated disease: only three patients were treated with cis-platinum chemotherapy.
Analysis of national data from the USA failed to show any improvement in survival for patients with seminoma between 1973-76 and 1976-79 (Li et al., 1982) . The survival rate was 92% during both periods.
The T-stage of the primary tumour affected prognosis: patients with tumours beyond TI had a significantly lower long term survival (Figure 2 ). Advanced T-stage of the primary tumour might signal the biologically more aggressive tumours. Unfortunately T-stage takes no account of other possible harbingers of aggressive tumour behaviour such as vascular invasion (Sandeman & Matthews, 1979) .
The results of prophylactic radiotherapy for adequately staged patients with clinical Stage I disease are excellent: 96.11% long term survival overall; 100% survival for patients with TI primary tumours. These results are achieved without excessive morbidity. The relatively high incidence of duodenal ulcer in patients treated for seminoma is puzzling and has been noted by others (Peckham et al., 1985) . We have not observed the problem in patients treated with similar radiation fields but higher dose, for nonseminomatous tumours (Duncan & Munro, 1985) .
No attempt was made routinely to assess fertility after treatment. A total of 5 patients had proven infertility: the true number is almost certainly higher. The radiation dose to the remaining testis can, by extra shielding, be reduced below the levels achieved in this study (Kubo & Shipley, 1982) with consequent improvement in the fertility rate after treatment.
Second testicular primary tumours were relatively frequent: 4/152 (2.6%). This represents a relative risk of x500 compared with the normal male population, similar findings have been described in a larger series (Hay et al., 1984) . This is in contrast to patients with NSGCT where there is no apparent excess of second testicular tumours (Duncan & Munro, 1985) . Effective chemotherapy is now available for disseminated seminoma (Schuette et al., 1985; Peckham et al., 1985) . In the study from the Royal Marsden Hospital (Peckham et al., 1985) It is now considered reasonable not to treat the retroperitoneum prophylactically in patients with Stage I NSGCT and enter these patients in surveillance studies (Peckham et al., 1983; . The arguments used to support such a policy cannot simply be translated to justify a similar policy for Stage I seminomas. Seminomas are different in their biology and natural history from NSGCT. The most serious defect in any argument in favour of a policy of surveillance for Stage I seminoma is the lack of adequate tumour markers for the tumour. Lactate dehydrogenase levels correlate roughly with the amount of tumour present but the enzyme is in no way a specific monitor of disease activity. Placental alkaline phosphatase, particularly when detected using the monoclonal antibody H17E2, may prove a useful marker for seminoma but raised marker levels in patients who smoke cloud the issue Epenetos et al., 1985) .
Data from studies of surveillance in patients with Stage I seminoma are preliminary, the follow-up is short since most of these studies only started in 1982 seminoma, whose staging investigations included lymphography and CT scanning, have a relapse rate of 2/150 (1.3%) after prophylactic radiotherapy to the para-aortic nodes (Thomas, 1985) . The data on tumour size at diagnosis (Table I) The relationship between tumour size and the duration of symptoms is complex (Figure 4 ). There is a paradoxical decrease in the size of the primary tumour for patients with symptom duration of more than 110 days before treatment. It is difficult to know whether this apparent decrease is real or artefactual: if it is real it is hard to explain.
The results from Edinburgh show that prophylactic retroperitoneal irradiation, using the fields and dose described, produces excellent survival for properly staged patients with Stage I seminoma. We accept that many patients, who do not have micro-metastatic disease in the retroperitoneum, are being treated unneccessarily. Nevertheless, the morbidity of treatment is low enough, and the overall survival high enough, to justify such a policy. The few patients who relapse can be effectively treated with chemotherapy. (Peckham et al., 1985) but at a high price in terms ot toxicity. Radiotherapy to the retroperitoneal nodes will cure approximately 80% of such patients and its toxicity is less than that of chemotherapy. The 20% who are not cured by radiation therapy will require salvage chemotherapy. On balance, a policy of initial treatment with radiotherapy can be justified for patients with Stage IIA or IIB disease; as chemotherapy for seminoma becomes less toxic this balance may change in favour of initial treatment with cytotoxic drugs.
